Matthew Kulke is an American cancer researcher. He is the Chief of
Hematology
Hematology ( always spelled haematology in British English) is the branch of medicine concerned with the study of the cause, prognosis, treatment, and prevention of diseases related to blood. It involves treating diseases that affect the produc ...
/
Oncology, co-director of the
BU/
BMC Cancer Center and "Zoltan Kohn Professor" at the
Boston University School of Medicine
The Boston University Chobanian & Avedisian School of Medicine, formerly the Boston University School of Medicine, is one of the graduate schools of Boston University. Founded in 1848, the medical school was the first institution in the world ...
. His work has shed light on the molecular characteristics of
neuroendocrine tumors and has led to the development of multiple new treatments for this condition.
His research studies led to the development and approval of
telotristat ethyl, a
tryptophan hydroxylase inhibitor, for the treatment of patients with
carcinoid syndrome. He has also contributed to early and late stage clinical trials of
temozolomide
Temozolomide (TMZ), sold under the brand name Temodar among others, is a medication used to treat brain tumors such as glioblastoma and anaplastic astrocytoma. Text was copied from this source which is © European Medicines Agency. Reproduction i ...
,
sunitinib
Sunitinib, sold under the brand name Sutent, is a medication used to treat cancer. It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and i ...
,
everolimus, and
peptide receptor radiotherapy for neuroendocrine tumors.
Education
Kulke received his undergraduate degree from
Princeton University, his
M.D. from the
University of California, San Francisco School of Medicine
The UCSF School of Medicine is the medical school of the University of California, San Francisco and is located at the base of Mount Sutro on the Parnassus Heights campus in San Francisco, California. Founded in 1864 by Hugh Toland, it is the o ...
, completed a residency in internal medicine at
Brigham and Women's Hospital
Brigham and Women's Hospital (BWH) is the second largest teaching hospital of Harvard Medical School and the largest hospital in the Longwood Medical and Academic Area, Longwood Medical Area in Boston, Massachusetts. Along with Massachusetts Gener ...
and a fellowship in Medical Oncology at
Dana-Farber Cancer Institute.
He holds a master's degree in medical science from
Harvard Medical School.
Career
After his education, Kulke subsequently joined the faculty at Dana-Farber Cancer Institute and Harvard Medical School where he rose to the rank of Professor of Medicine and was the founding director of the neuroendocrine tumor program.
He has served in his current role at Boston University since 2018. His accomplishments in the field have been recognized at the national and international level. He has served as chair of the
National Cancer Institute's Neuroendocrine Tumor Task Force from 2011-2014,
as chair of the North American Neuroendocrine Tumor Society from 2014-2016, and as chair the
National Comprehensive Cancer Network
National Comprehensive Cancer Network (NCCN) is an alliance of 32 cancer centers in the United States, most of which are designated by the National Cancer Institute (one of the U.S. National Institutes of Health) as comprehensive cancer centers. It ...
’s neuroendocrine tumor guidelines committee from 2010-2017.
References
External links
Faculty profileat
Boston University
*
{{DEFAULTSORT:Kulke, Matthew Helmut
Year of birth missing (living people)
Living people
Princeton University alumni
University of California, San Francisco alumni
Harvard Medical School alumni
Harvard Medical School faculty
Boston University faculty